Health Care & Life Sciences » Pharmaceuticals | Boryung Pharmaceutical Co. Ltd.

Boryung Pharmaceutical Co. Ltd. | Cash Flow

Fiscal year is January-December. All values KRW Millions.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
14,127
21,591
20,301
5,614
56,478
21,897
Depreciation, Depletion & Amortization
10,553
11,125
12,781
15,187
16,246
16,142
Other Funds
8,676
6,245
4,261
11,600
77,979
8,748
Funds from Operations
33,356
38,961
37,343
32,401
5,255
46,787
Changes in Working Capital
4,828
29,620
20,228
23,038
19,008
7,249
Net Operating Cash Flow
28,527
9,341
17,114
9,363
24,264
39,538
Capital Expenditures
13,094
16,708
20,322
26,829
67,032
Sale of Fixed Assets & Businesses
5,916
-
34
667
2
Purchase/Sale of Investments
78
61
228
56,969
38,977
Net Investing Cash Flow
7,046
16,663
20,515
32,395
24,543
Cash Dividends Paid - Total
1,010
1,062
1,481
1,557
1,619
Issuance/Reduction of Debt, Net
20,531
5,282
20,275
31,831
40,887
Net Financing Cash Flow
21,407
3,139
19,119
38,521
39,122
Net Change in Cash
146
4,136
15,911
4,228
9,973
Free Cash Flow
18,039
6,521
900
15,708
87,214
Other Sources
326
-
1
1,587
3,615
Change in Capital Stock
134
1,082
325
5,133
147
Exchange Rate Effect
220
48
192
991
288
Other Uses
117
16
-
-
105

About Boryung Pharmaceutical Co.

View Profile
Address
Boryung Building
Seoul SL 03127
Korea, Republic Of
Employees -
Website http://www.boryung.co.kr
Updated 07/08/2019
Boryung Pharmaceutical Co., Ltd. engages in the manufacture of of drug products. Its main products include Kanarb, Dukarb, Tuvero, TODULA, BESTO, and gelfosM. Its products include cardiovascular, antibiotics, anticancer, amino acid, cosmetics, gastrointestinal, and API.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.